Safety and toxicity of combined oclacitinib and carboplatin or doxorubicin in dogs with solid tumors: a pilot study.

Laura E BarrettHeather L GardnerLisa G BarberAbbey SadowskiCheryl A London

Published in: BMC veterinary research (2019)

Oclacitinib is well tolerated when given in combination with carboplatin or doxorubicin. Future work is needed to explore whether efficacy is enhanced in this setting.

Keyphrases

phase ii study
drug delivery
cancer therapy
phase iii
oxidative stress
current status
clinical trial
randomized controlled trial
rectal cancer
study protocol
double blind
placebo controlled